Richter Gedeon Vegyeszeti Gyar Rt

Richter Gedeon Nyrt.

Gyorgy Domany

Bela Hegedus

Kalman Harsanyi

Katalin Saghy

Eva Againe Csongor

Istvan Szabadkai

Laszlo Szporny

Elemer Ezer

Ferenc Trischler

Judit Matuz

Gyorgy Hajos

Bela Kiss

Judit Laszy

Peter Bod

Eva Fekecs

Istvan Gyertyan

Sandor Farkas

Erik Bogsch

Eva Schmidt

Gizella Bartane Szalai

Agnes Lampert

Eva Gai Nee Csongor

Zsolt Komlodi

Andras Rado

Egon Karpati

Csaba Szantay

Janos Kreidl

Gyorgy Fekete

Laszlo Czibula

Erzsebet Lapis

Istvan Laszlovszky

Lajos Toldy

Tibor Balogh

Jozsef Reiter

Endre Kasztreiner

Istvan Schon

Adam Sarkadi

Tibor Lang

Janos Borvendeg

Maria Farkas Nee Kirjak

Peter Tetenyi

Sandor Szabo

Tibor Acs

Katalin Pallagi

Ferenc Sebok

Margit Bidlo Nee Igloy

Ida Deutsch Nee Juhasz

Gyorgy Ferenczy

Bela Benke

Ferenc Morasz

Hajnalka V Petho

Istvan Greiner

Margit Pellioniszne Paroczai

Krisztina Szekely

Arpad Lazar

Marta K Pap

Oszkar Fuchs

Monika Csejtei

Tibor Somogyi

Feranc Auth

Marta Renyei

Eszter Thuroczyne Kalman

Gyorgyi Szabone Komlosi

Katalin Varga

Kristztina Szekely

Anna Lauko

Maria Demeter

The present invention relates to new dopamine Dand Dligands of formula (I): wherein R1, R2 and Q are as described herein, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates and/or polymorphs thereof. The invention also relates to processes for preparing the same, to compositions containing the same and to their use in the treatment and/or prevention of conditions which requires modulation of dopamine receptors.

[object Object]

The present invention relates to novel monohydrochloride, dihydrochloride, monohydrobromide, maleate and methanesulphonate salts of trans 4-{2-[4-(2,3-dichlorophenyl)-piperazine-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine and/or their hydrates and/or solvates. Moreover, the invention relates to the process for preparing the salts and their hydrates and/or solvates, to their use in the treatment and/or prevention of conditions which require modulation of dopamine receptor and to pharmaceutical compositions containing them.

Process for preparing a substituted allylamine derivative and the salts thereof

2-methoxyphenylpiperazine derivatives

The invention relates to novel pyridine derivatives of formula (I), ##STR1## wherein Q stand for a nitro or cyano group; and

Pyridine derivatives and pharmaceutical compositions containing them

2,3-thiomorpholinedione-2-oxime derivatives and pharmaceutical

The present invention relates to novel 2-thiazolidinone derivatives of the general formula (I), ##STR1## wherein A stands for hydrogen, halogen or a C.sub.1-4 alkyl, C.sub.1-4 alkoxy or nitro group; and

2-thiazolidinone derivatives, pharmaceutical compositions containing

The invention relates to a new process for the preparation of N-sulfamyl-3-(2-guanidinothiazol-4-yl-methylthio)-propionitrile (famotidine) of the formula (I) ##STR1## by S-alkylation of 2-guanidino-thiazol-4-yl-methanethiol obtained from S-(2-guanidino-thiazol-4-yl-methyl)-isothiourea dihydrochloride of the formula (III) ##STR2## by in situ treatment with a base, which comprises carrying out S-alkylation with a N-sulfamyl-3-halopropionamidine of the formula (II) ##STR3## wherein X stands for halogen.

Process for the preparation of

The invention relates to new propionamidine derivatives of formula (I) ##STR1## wherein X is halogen, and to a process for their preparation. According to the invention compounds of the formula (I) are prepared by reacting a 3-halopropionitrile of the formula (III) ##STR2## wherein X is as defined above, with sulfamide of the formula (II) ##STR3## in the presence of a hydrogen halide. Compounds of the formula (I) are useful intermediates in the preparation of famotidine.

N-sulfamyl-3-halopropionamidines

New thiazolidine compounds of the formula (I) having anti-ulcer activity are disclosed: ##STR1## wherein Ar is a 2-furyl or a phenyl, naphthyl or pyridyl group optionally substituted by one or more C.sub.1-4 -alkyl, C.sub.1-4 -alkoxy, halo-C.sub.1-4 -alkoxy, dihalomethyl, trihalomethyl, hydroxyl or nitro groups or by a group of the formula (II), ##STR2## wherein Y is nitrogen or CH;

Thiazolidine derivatives, process for the preparation and pharmaceutical

The invention relates to the new monohydrate of N-methyl-N'-{2-[(5-methylimidazol-4-yl)-methylthio]-ethyl}-N'-cyanoguanidi ne (cimetidine), a histamine-H.sub.2 receptor antagonist which is called N-methyl-N'-{2-[(5-methylimidazol-4-yl)-methylthio]-ethyl}-N'-cyanoguanidi ne H (cimetidine H) as well as to a process for the preparation of same, which comprises pouring a hot, homogeneous aqueous solution of N-methyl-N'-{2-[(5-methylimidazol-4-yl)-methylthio]-ethyl}-N'-cyanoguanidi ne, optionally containing also methylamine, onto ice and separating the N-methyl-N'-{2-[(5-methylimidazol-4-yl)-methylthio]-ethyl}-N'-cyanoguanidi ne monohydrate.

Cimetidine monohydrate

The invention relates to a new crystal modification of N-methyl-N'-{2-[(5-methylimidazol-4-yl)-methylthio]-ethyl}-N'-cyanoguanidi ne (cimetidine), a histamine H-2 receptor antagonist having the Formula (I) ##STR1## as well as to a process for preparing same. In the description, this new modification is named N-methyl-N'-{2-[(5-methylimidazol-4-yl)-methylthio]-ethyl}-N'-cyanoguanidi ne Z (cimetidine Z).

Cimetidine Z, a new crystal modification of cimetidine

Growing community of inventors

Budapest, Hungary

Gyorgy Domany